Good T Cells, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 21, 2027The maintenance fee for Novel Fusion Protein, and Pharmaceutical Composition For Preventing Or Treating Cancer, Containing Same (US 11,820,801) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 1 fee due Jun 3, 2027The maintenance fee for Fusion protein comprising transcription modulation domain of p65 and protein transduction domain, and uses thereof (US 10,494,411) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
- 1 fee due Jul 28, 2027The maintenance fee for Composition Containing Smad Protein for Treatment of Autoimmune Diseases, a Fusion Protein Comprising Smad Protein, an Expression Vector and a Method for Preparing the Same (US 10,544,196) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for Composition for Prevention or Treatment of Hair Loss (US 11,890,364) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
- 2 fees due Sep 5 to 19, 2027 · next Sep 5
- 1 fee due Oct 30, 2027The maintenance fee for Method for activating T cells for cancer treatment (US 11,969,463) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,546,221 | Fusion Protein Having Transcription Factor Transactivation-Regulating Domain and Protein Transduction Domain, and Transcription Factor Function Inhibitor Comprising the Same In force · High confidence | In force | High confidence | |
| US 11,091,538 | Novel Use of Regulatory T Cell-Specific Surface Protein LRIG-1 In force · High confidence | In force | High confidence | |
| US 11,655,287 | Novel Use of Regulatory T Cell-Specific Surface Protein LRIG-1 In force · High confidence | In force | High confidence | |
| US 11,932,686 | Novel Use of Regulatory T Cell-Specific Surface Protein LRIG-1 In force · High confidence | In force | High confidence | |
| US 10,494,411 | Fusion protein comprising transcription modulation domain of p65 and protein transduction domain, and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,544,196 | Composition Containing Smad Protein for Treatment of Autoimmune Diseases, a Fusion Protein Comprising Smad Protein, an Expression Vector and a Method for Preparing the Same In force · High confidence | In force | High confidence | |
| US 11,414,467 | Fusion protein comprising transcription modulation domain of p65 and protein transduction domain, and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,999,785 | Binding molecule specific for Lrig-1 protein and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,890,364 | Composition for Prevention or Treatment of Hair Loss In force · High confidence | In force | High confidence | |
| US 11,820,801 | Novel Fusion Protein, and Pharmaceutical Composition For Preventing Or Treating Cancer, Containing Same In force · High confidence | In force | High confidence |
Also on record, not counted in the 13: 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 4 abandoned · 7 no status recorded